background
respiratori
virus
caus
signific
morbid
hospit
among
children
recent
advanc
diagnost
improv
abil
identifi
viral
pathogen
avoid
prolong
hospit
unnecessari
antibiot
use
molecular
diagnost
test
recent
fda
approv
esensor
genmark
dx
method
standard
care
identifi
respiratori
viral
pathogen
larg
pediatr
referr
facil
util
direct
fluoresc
antibodi
dfa
viral
cultur
dfaneg
specimen
genmark
probe
test
ad
standardofcar
test
total
sampl
inpati
respiratori
season
sampl
neg
dfacultur
posit
either
dfa
viral
cultur
use
clinic
data
collect
length
stay
calcul
day
n
exclud
hospit
unlik
relat
viral
ill
result
esensor
rvp
identifi
viral
nucleic
acid
sampl
compar
standard
care
thu
tripl
diagnost
yield
result
viru
list
tabl
associ
longer
hospit
higher
acuiti
among
subject
multipl
virus
detect
influenza
rsv
alon
longer
length
stay
higher
acuiti
associ
coronaviru
common
coronaviru
identifi
associ
remain
signific
younger
subject
like
rsv
hrv
viru
conclus
improv
sensit
esensor
rvp
identifi
mani
infect
current
standard
care
coronaviru
especi
could
potenti
repres
virul
pathogen
associ
prolong
hospit
higher
acuiti
detect
viru
hospit
child
predict
higher
acuiti
ill
longer
hospit
disclosur
w
kimberlin
gsk
grant
investig
serv
studi
site
clinic
trial
conduct
gsk
moni
went
univers
grant
recipi
gilead
grant
investig
serv
studi
site
clinic
trial
conduct
gilead
moni
went
univers
grant
recipi
n
prichard
genmark
investig
mark
prichard
receiv
research
fund
genmark
defray
cost
associ
studi
research
support
